Drugs / Bevacizumab-IRDye800CW
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06095362 | Nov 2021 → Oct 2023 | thyroid gland carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT04212793 | Oct 2020 → Oct 2022 | pituitary gland adenoma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT03558724 | Oct 2018 → Oct 2022 | esophageal cancer | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 1 | NCT02129933 | Apr 2014 → Nov 2016 | esophageal cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT02113202 | Mar 2014 → Oct 2015 | classic or attenuated familial adenomatous polyposis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT01972373 | Oct 2013 → Dec 2016 | rectal cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT01508572 | Oct 2011 → Nov 2014 | breast cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03620292 | Apr 2019 → Dec 2021 | hilar cholangiocarcinoma | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1/2 | NCT03913806 | May 2018 → Dec 2019 | soft tissue sarcoma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05359874 | Jun 2021 → Mar 2023 | breast cancer | Technical University of Munich | Withdrawn | No outcome recorded |
| Phase 2 | NCT03877601 | Jul 2019 → Sep 2021 | Barrett esophagus | University Medical Center Groningen | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bevacizumab-IRDye 800CW | “Therefore recently the near-infrared fluorescent tracer bevacizumab-IRDye 800CW has been developed.” NCT01508572 ↗ |
| Known as | Bevacizumab | “Bevacizumab is a genetically engineered humanized monoclonal antibody that is directed against VEGF and is already therapeutically approved for the treatment of breast and...” NCT05359874 ↗ |
| Known as | bevacizumab-IDRye800CW | “The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer...” NCT01508572 ↗ |
| Known as | Bevacizumab800CW | “TRIAL REGISTRATION: NCT04212793 / Study Details| Detection of PitNET Tissue During TSS Using Bevacizumab800CW| ClinicalTrials.gov.” PMID 39390132 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “bevacizumab (a VEGF targeting humanized monoclonal antibody)” NCT01508572 ↗ |
| Route | Intravenous | “4.5 mg of bevacizumab-IRDye 800CW will be administered intravenously” NCT01508572 ↗ |
| Target | VEGFA | “targeting vascular endothelial growth factor A (VEGF-A)” PMID 39390132 ↗ Oct 2024 |